Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort

医学 慢性阻塞性肺病 肺活量 肺功能测试 内科学 肺活量测定 哮喘 气道阻塞 气道 扩散能力 外科 肺功能
作者
Giorgia Radicioni,Agathe Ceppe,Amina A. Ford,Neil E. Alexis,R. Graham Barr,Eugene R. Bleecker,Stephanie A. Christenson,Christopher B. Cooper,MeiLan K. Han,Nadia N. Hansel,Annette T. Hastie,Eric A. Hoffman,Richard E. Kanner,Fernando J. Martínez,Esin Özkan,Robert Paine,Prescott G. Woodruff,Wanda K. O’Neal,Richard C. Boucher,Mehmet Kesimer
出处
期刊:The Lancet Respiratory Medicine [Elsevier]
卷期号:9 (11): 1241-1254 被引量:108
标识
DOI:10.1016/s2213-2600(21)00079-5
摘要

Background We previously described the contributions of increased total airway mucin concentrations to the pathogenesis and diagnosis of the chronic bronchitic component of chronic obstructive pulmonary disease (COPD). Here, we investigated the relative contribution of each of the major airway gel-forming mucins, MUC5AC and MUC5B, to the initiation, progression, and early diagnosis of airways disease in COPD. Methods SPIROMICS was a multicentre, observational study in patients aged 40–80 years recruited from six clinical sites and additional subsites in the USA. In this analysis, MUC5AC and MUC5B were quantitated by stable isotope-labelled mass spectrometry in induced sputum samples from healthy never-smokers, ever-smokers at risk for COPD, and ever-smokers with COPD. Participants were extensively characterised using results from questionnaires, such as the COPD assessment test (CAT) and St George's Respiratory Questionnaire; quantitative CT, such as residual volume/total lung capacity ratio (RV/TLC) and parametric response mapping-functional small airway disease (PRM-fSAD); and pulmonary function tests, such as FEV1, forced vital capacity (FVC), and forced expiratory flow, midexpiratory phase (FEF25–75%). Absolute concentrations of both MUC5AC and MUC5B were related to cross-sectional (baseline, initial visit) and 3-year follow-up longitudinal data, including lung function, small airways obstruction, prospective acute exacerbations, and smoking status as primary outcomes. This study is registered with ClinicalTrials.gov (NCT01969344). Findings This analysis included 331 participants (mean age 63 years [SEM 9·40]), of whom 40 were healthy never-smokers, 90 were at-risk ever-smokers, and 201 were ever-smokers with COPD. Increased MUC5AC concentrations were more reliably associated with manifestations of COPD than were MUC5B concentrations, including decreased FEV1 and FEF25–75%, and increased prospective exacerbation frequency, RV/TLC, PRM-fSAD, and COPD assessment scores. MUC5AC concentrations were more reactive to cigarette smoke exposure than were MUC5B concentrations. Longitudinal data from 3-year follow-up visits generated a multivariate-adjusted odds ratio for two or more exacerbations of 1·24 (95% CI 1·04–1·47, p=0·015) for individuals with high baseline MUC5AC concentration. Increased MUC5AC, but not MUC5B, concentration at baseline was a significant predictor of FEV1, FEV1/FVC, FEF25–75%, and CAT score decline during the 3-year follow-up. Moreover, current smokers in the at-risk group showed raised MUC5AC concentrations at initial visits and decreased lung function over 3 years. By contrast, former smokers in the at-risk group showed normal MUC5AC concentrations at the initial visit and preserved lung function over 3 years. Interpretation These data indicate that increased MUC5AC concentration in the airways might contribute to COPD initiation, progression, exacerbation risk, and overall pathogenesis. Compared with MUC5B, greater relative changes in MUC5AC concentrations were observed as a function of COPD severity, and MUC5AC concentration seems to be an objective biomarker to detect disease in at-risk and pre-COPD individuals. These data suggest that MUC5AC-producing pathways could be potential targets for future therapeutic strategies. Thus, MUC5AC could be a novel biomarker for COPD prognosis and for testing the efficacy of therapeutic agents. Funding National Institutes of Health; National Heart, Lung, and Blood Institute.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Raylihuang应助zho采纳,获得10
1秒前
善学以致用应助zho采纳,获得10
2秒前
Lucas应助zho采纳,获得10
2秒前
JamesPei应助zho采纳,获得10
2秒前
SciGPT应助zho采纳,获得10
2秒前
结实的小土豆完成签到 ,获得积分10
5秒前
6秒前
8秒前
打打应助zpy采纳,获得10
8秒前
大脑袋媛媛完成签到,获得积分20
9秒前
QQQ发布了新的文献求助10
11秒前
11秒前
lingo发布了新的文献求助10
11秒前
11秒前
健壮元绿发布了新的文献求助10
13秒前
wroy完成签到,获得积分10
13秒前
zZ发布了新的文献求助10
13秒前
科目三应助zho采纳,获得10
15秒前
Lucas应助zho采纳,获得10
15秒前
千里共婵娟应助zho采纳,获得20
15秒前
希望天下0贩的0应助zho采纳,获得10
15秒前
善学以致用应助zho采纳,获得10
15秒前
在水一方应助zho采纳,获得10
15秒前
坚强的严青应助zho采纳,获得30
15秒前
我是老大应助zho采纳,获得10
15秒前
遥远的尧应助zho采纳,获得10
15秒前
大个应助zho采纳,获得10
15秒前
16秒前
Ergou完成签到 ,获得积分10
16秒前
18秒前
18秒前
19秒前
20秒前
zpy发布了新的文献求助10
20秒前
shin2333完成签到,获得积分10
20秒前
22秒前
发嗲的康完成签到,获得积分10
23秒前
mumufan发布了新的文献求助10
23秒前
打打应助海绵宝宝采纳,获得10
25秒前
zpy完成签到,获得积分10
26秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
花菁类近红外荧光染料的合成及光学性能研究 500
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3161216
求助须知:如何正确求助?哪些是违规求助? 2812648
关于积分的说明 7895876
捐赠科研通 2471484
什么是DOI,文献DOI怎么找? 1316042
科研通“疑难数据库(出版商)”最低求助积分说明 631074
版权声明 602112